Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Name:
e000219.full.pdf
Size:
743.9Kb
Format:
PDF
Description:
Full text open access article
Authors
Blackhall, Fiona HRoss Camidge, D
Shaw, A
Soria, J
Solomon, B
Mok, T
Hirsh, V
Jänne, P
Shi, Y
Yang, P
Pas, T
Hida, T
Carpeño, J
Lanzalone, S
Polli, A
Iyer, S
Reisman, A
Wilner, K
Kim, D
Affiliation
Institute of Cancer Sciences, Manchester University and Christie Hospital NHS Foundation Trust, Manchester, UKIssue Date
2017
Metadata
Show full item recordAbstract
Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in ALK-positive NSCLC.Citation
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. 2017, 2 (3):e000219 ESMO OpenJournal
ESMO OpenDOI
10.1136/esmoopen-2017-000219PubMed ID
29209525Type
ArticleLanguage
enISSN
2059-7029ae974a485f413a2113503eed53cd6c53
10.1136/esmoopen-2017-000219